The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Efficacy of Spironolactone Therapy in Patients With True Resistant Hypertension
Abstract
The role of spironolactone in resistant hypertension management is unclear. The aim of this prospective trial was to evaluate the antihypertensive effect of spironolactone in patients with true resistant hypertension diagnosed by ambulatory blood pressure monitoring. A total of 175 patients had clinical and complementary exams obtained at baseline and received spironolactone in doses of 25 to 100 mg/d. A second ambulatory blood pressure monitoring was performed after a median interval of 7 months. Paired Student t test was used to assess differences in blood pressure before and during spironolactone administration, and multivariate analysis adjusted for age, sex, and number of antihypertensive drugs to assess the predictors of blood pressure fall. There were mean reductions of 16 and 9 mm Hg, respectively, in 24-hour systolic and diastolic blood pressures (95% CIs: 13 to 18 and 7 to 10 mm Hg; P <0.001). Office systolic blood pressure and diastolic blood pressure also decreased (14 and 7 mm Hg). Controlled ambulatory blood pressure was reached in 48% of patients. Factors associated with better response were higher waist circumference, lower aortic pulse wave velocity, and lower serum potassium. No association with plasma aldosterone or aldosterone:renin ratio was found. Adverse effects were observed in 13 patients (7.4%). A third ambulatory blood pressure monitoring performed in 78 patients after a median of 15 months confirmed the persistence of the spironolactone effect. In conclusion, spironolactone administration to true resistant hypertensive patients is safe and effective in decreasing blood pressure, especially in those with abdominal obesity and lower arterial stiffness. Its addition to an antihypertensive regimen as the fourth or fifth drug is recommended.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, in patients with obesity and treatment-resistant hypertension who were treated with spironolactone, the resulting reductions in BP did not correlate with plasma aldosterone concentration73,74.”
From Obesity, kidney dysfunction and hypertension: mechanistic links (2019) · cites this paper as [74]
In the citing paper
“Administration of MR antagonists provides significant antihypertensive benefit in treatment resistant obese patients, although there was no correlation between plasma aldosterone levels and BP responses to MR blockade52,53.”
From Obesity-Induced Hypertension: Interaction of Neurohumoral and Renal Mechanisms (2015) · cites this paper as [52]
In the citing paper
“In patients who are not overtly volume overloaded but who have evidence of low renin status or salt sensitivity of BP, mineralocorticoid receptor antagonists (spironolactone or eplerenone) are more successful than α- or β-blockers.373,377”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [377]
In the citing paper
“Recent reports document the efficacy of mineralocorticoid receptor blockade (Figure 3, step 3, and Table 4) to improve BP in patients with RH.373–377”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [377]
In the citing paper
“These observations are also consistent with the beneficial effects of mineralocorticoid receptor blockade on blood pressure in obese subjects even in those displaying resistant hypertension (55).”
From Obesity-Associated Hypertension: Recent Progress in Deciphering the Pathogenesis (2014) · cites this paper as [55]
Citations
Cites
Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence
Morisky, D. E., Green, L. W., & Levine, D. M. (1986) · Medical Care · doi:10.1097/00005650-198601000-00007 · Cited by 5,399
Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method.
Devereux, R. B., & Reichek, N. (1977) · Circulation · doi:10.1161/01.cir.55.4.613 · Cited by 4,499
Laurent, S., Boutouyrie, P., Asmar, R., Gautier, I., Laloux, B., Guize, L., Ducimetiere, P., & Benetos, A. (2001) · Hypertension · doi:10.1161/01.hyp.37.5.1236 · Cited by 3,856
Resistant Hypertension: Diagnosis, Evaluation, and Treatment
Calhoun, D. A., Jones, D. W., Textor, S. C., Goff, D. C., Murphy, T. P., Toto, R. D., White, A. J., Cushman, W. C., White, W. B., Sica, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.189141 · Cited by 2,240
Funder, J. W., Carey, R. M., Fardella, C., Gomez-Sanchez, C. E., Mantero, F., Stowasser, M., Young, W. F., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0104 · Cited by 1,554
Resistant Hypertension: Diagnosis, Evaluation, and Treatment
Calhoun, D. A., Jones, D. W., Textor, S. C., Goff, D. C., Murphy, T. P., Toto, R. D., White, A. J., Cushman, W. C., White, W. B., Sica, D. A., et al. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.189141 · Cited by 1,416
Asmar, R., Benetos, A., Topouchian, J., Laurent, P., Pannier, B., Brisac, A.-M., Target, R., & Levy, B. I. (1995) · Hypertension · doi:10.1161/01.hyp.26.3.485 · Cited by 1,376
Hyperaldosteronism Among Black and White Subjects With Resistant Hypertension
Calhoun, D. A., Nishizaka, M. K., Zaman, M. A., Thakkar, R. B., & Weissmann, P. (2002) · Hypertension · doi:10.1161/01.hyp.0000040261.30455.b6 · Cited by 763
Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension
Chapman, N., Dobson, J., Wilson, S. L., Dahlöf, B., Sever, P., Wedel, H., & Poulter, N. R. (2007) · Hypertension · doi:10.1161/01.hyp.0000259805.18468.8c · Cited by 630
Efficacy of low-dose spironolactone in subjects with resistant hypertension
Nishizaka, M. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)01032-x · Cited by 500
Cited by
Sorted by citations
Items 101–200 of 234
Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?
Packer, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf645 · Cited by 21
Shlomai, G., Sella, T., Sharabi, Y., Leibowitz, A., & Grossman, E. (2014) · Hypertension Research · doi:10.1038/hr.2014.77 · Cited by 14
White, W. B., Bisognano, J. D., Calhoun, D. A., Townsend, R. R., Aronow, H. D., Bhatt, D. L., & Bakris, G. L. (2014) · Cited by 13
Resistant hypertension: Renal denervation or intensified medical treatment?
Morganti, A., & Mancia, G. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.12.010 · Cited by 13
New Therapeutic Approaches to Resistant Hypertension
Schlaich, M. P., Krum, H., & Esler, M. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0119-1 · Cited by 13
Treatment Considerations With Aldosterone Receptor Antagonists
Sica, D. A., & Flack, J. M. (2010) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2010.00377.x · Cited by 13
Decoding resistant hypertension signalling pathways
Parreira, R. C., Lacerda, L. H. G., Vasconcellos, R., Lima, S. S., Santos, A. K., Fontana, V., Sandrim, V. C., & Resende, R. R. (2017) · Clinical Science · doi:10.1042/cs20171398 · Cited by 13
Khan, N. A., Herman, R. J., Quinn, R. R., Rabkin, S. W., Ravani, P., Tobe, S. W., Feldman, R. D., Wijeysundera, H. C., & Padwal, R. S. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.07.008 · Cited by 12
Effectiveness of the Direct Renin Inhibitor, Aliskiren, in Patients With Resistant Hypertension
Yoshitomi, Y., Kawanishi, K., Yamaguchi, A., Sakurai, S.-I., Minai, K., Ishii, T., Tarutani, Y., Tsujibayashi, T., Kaneki, M., Saitou, Y., et al. (2013) · International Heart Journal · doi:10.1536/ihj.54.88 · Cited by 12
The possibility of resistant hypertension during the treatment of hypertensive patients
Nishikawa, T., Omura, M., Saito, J., & Matsuzawa, Y. (2013) · Hypertension Research · doi:10.1038/hr.2013.107 · Cited by 12
Primary aldosteronism: A contrarian view
Kaplan, N. M. (2011) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-011-9160-x · Cited by 11
Ali, Y. M., Dohi, K., Okamoto, R., Katayama, K., & Ito, M. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14630 · Cited by 11
Difficult-to-Treat or Resistant Hypertension: Etiology, Pathophysiology, and Innovative Therapies
Papademetriou, V., Tsioufis, C. P., Gradman, A. H., & Punzi, H. A. (2011) · International Journal of Hypertension · doi:10.4061/2011/438198 · Cited by 11
Refractory Hypertension: a Narrative Systematic Review with Emphasis on Prognosis
Bacan, G., Ribeiro-Silva, A., Oliveira, V. A., Cardoso, C. R. L., & Salles, G. F. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01165-w · Cited by 10
Self-citationRenin–angiotensin–aldosterone system and blood pressure regulation
Seravalle, G., & Grassi, G. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-96120-2.00002-9 · Cited by 10
Update on diagnosis and treatment of resistant hypertension.
Pimenta, E. (2011) · Iranian Journal of Kidney Diseases · Cited by 10
Mansur, S. J., Hage, F. G., & Oparil, S. (2010) · Current Cardiology Reports · doi:10.1007/s11886-010-0140-7 · Cited by 10
Chedier, B., Cortez, A. F., Roderjan, C. N., Cavalcanti, A. D. H., Carlos, F., Dussoni, B., & Muxfeldt, E. S. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-00406-2 · Cited by 12
Self-citationMaiolino, G., Azzolini, M., & Rossi, G. P. (2015) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2015.00003 · Cited by 9
Targeting the aldosterone pathway in cardiovascular disease
Gustafsson, F., Azizi, M., Bauersachs, J. K., Jaisser, F., & Rossignol, P. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.01004.x · Cited by 9
Václavík, J., Sedlák, R., Jarkovský, J., Kociánová, E., & Táborský, M. (2012) · Biomedical Papers · doi:10.5507/bp.2012.078 · Cited by 9
Toušek, P., Widimsky, J., Jr., Rosa, J., Čurila, K., Branny, M., Nykl, I., Táborský, M., Václavík, J., & Widimský, P. (2014) · Cor et Vasa · doi:10.1016/j.crvasa.2014.04.004 · Cited by 9
Resistant Hypertension in Diabetes Mellitus
Bayliss, G. P., Weinrauch, L. A., & D’Elia, J. A. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0516-y · Cited by 9
Reviving the use of aldosterone inhibitors in treating hypertension in obesity
Huby, A.-C., & de Chantemèle, E. J. B. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00133.2015 · Cited by 9
Recent Advancements in the Treatment of Resistant Hypertension
Clark, D., Guichard, J. L., Calhoun, D. A., & Ahmed, M. I. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.01.2519 · Cited by 8
Update in Hypertension Therapy
Mankin, L. A. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.03.005 · Cited by 8
Blood pressure control in resistant hypertension: new therapeutic options
Grassi, G. M., Quarti‐Trevano, F., Brambilla, G., & Seravalle, G. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.138 · Cited by 8
Genetics and Pathophysiology of Essential Hypertension
Khullar, M. (2012) · InTech eBooks · doi:10.5772/1197 · Cited by 9
Obesity-Associated Hypertension: the Upcoming Phenotype in African-American Women
Samson, R., Qi, A., Jaiswal, A., Jemtel, T. H. L., & Oparil, S. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0738-x · Cited by 10
Should All Patients with Resistant Hypertension Receive Spironolactone?
Rosa, J., Zelinka, T., Petrák, O., Štrauch, B., Holaj, R., & Widimsky, J., Jr. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0690-1 · Cited by 8
Zheng, Y., Tang, L. Y., Chen, X., Cai, G., Li, W., Ni, Z., Shi, W., Ding, X., & Lin, H. (2018) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2018.1433193 · Cited by 7
Non-interventional management of resistant hypertension
Doumas, M. N. (2014) · World Journal of Cardiology · doi:10.4330/wjc.v6.i10.1080 · Cited by 7
Vonend, O., Quack, I., & Rump, L. C. (2010) · Wiener klinische Wochenschrift · doi:10.1007/s00508-010-1313-5 · Cited by 7
Cestário, E. D. E. S., Vilela-Martin, J. F., Cosenso‐Martin, L. N., Rubio, T. D. A., Uyemura, J. R. R., Lopes, V. D. S., Fernandes, L. A. B., Tácito, L. H. B., Moreno, H., & Yugar‐Toledo, J. C. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s383007 · Cited by 6
Diuretics for the Treatment of Hypertension
Sica, D. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_38 · Cited by 6
Evaluation and Pharmacologic Approach to Patients with Resistant Hypertension
Adams, M., Bellone, J. M., Wright, B. M., & Rutecki, G. W. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.01.2520 · Cited by 6
Escudero, J. A., Vecino, J. M. C., Veiras, S., Garcia, R., González, A., Escudero, J. A., Vecino, J. M. C., Baluja, A., Cabadas, R., Cariñena, A., et al. (2015) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2015.05.002 · Cited by 6
Václavík, J., Sedlák, R., Jarkovský, J., Kociánová, E., & Táborský, M. (2012) · Biomedical Papers · doi:10.5507/bp.2012.105 · Cited by 6
Efficacy of Spironolactone Therapy in Patients With True Resistant Hypertension
Elliott, W. J. (2011) · Yearbook of Cardiology · doi:10.1016/j.ycar.2011.01.107 · Cited by 6
Treatment Strategies to Prevent Renal Damage in Hypertensive Children
Czarniak, P., & Zurowska, A. M. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0423-2 · Cited by 6
Shuey, M. M., Perkins, B. A., Nian, H., Yu, C., Luther, J. M., & Brown, N. J. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-033100 · Cited by 5
Ali, Y. M., Gómez-Sánchez, E. P., & Gómez-Sánchez, C. E. (2022) · Endocrinology · doi:10.1210/endocr/bqac185 · Cited by 5
Guidelines for Use of Diuretics: A View From a Member of JNC 7
Carter, B. L. (2012) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2012.00621.x · Cited by 4
Phenotypic Characteristics of Resistant Hypertension in the Brazilian Population
de Faria, A. P., Sabbatini, A. R., Coca, A., & Moreno, H. (2013) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20130100 · Cited by 5
Should Patients with Obesity and Hypertension be Treated Differently from Those Who Are Not Obese?
Bloch, M. J., & Viera, A. J. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0418-z · Cited by 5
Recent advances in the management of resistant hypertension
Manolis, A. J., Kallistratos, M. S., Doumas, M. N., Pagoni, S., & Poulimenos, L. E. (2015) · F1000Prime Reports · doi:10.12703/p7-03 · Cited by 5
Fontenla, A., García‐Donaire, J. A., Hernández, F., Segura, J., Salgado‐Aranda, R., Cerezo, C., Ruilope, L. M., & Arribas, F. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2012.09.006 · Cited by 5
Fan, Y., Gao, W. D., Li, J., Fan, F., Qin, X., Liu, L., Cheng, X., Xu, X., Wang, X., Wang, B., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.02.059 · Cited by 5
Obesity, Fatty Kidney, and Hypertension: Potential Role of Aldosterone
Hall, M. E., Omoto, A. C. M., & Hall, J. E. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25627 · Cited by 5
Jansen, P. M., Verdonk, K., Imholz, B. P. M., Danser, A. H. J., & van den Meiracker, A. H. (2011) · International Journal of Hypertension · doi:10.4061/2011/368140 · Cited by 4
Lim, H., & Hamdani, W. N. (2024) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2023.45 · Cited by 4
Roles of Aldosterone Receptor Antagonists in Heart Failure, Hypertension, and Chronic Kidney Disease
Wang, A., Elshehadeh, R., Rao, D., Yap, E., Lee, A. E., Mossobir, F., Yu, J. J., Braaton, K., & Nguyen, T. V. (2016) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2015.10.023 · Cited by 4
Guasti, L., Gaudio, G. V., Lupi, A., D'Avino, M., Sala, C., Mugellini, A., Vulpis, V., Felis, S., Sarzani, R., Vanasia, M., et al. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s134826 · Cited by 4
Use of spironolactone in the treatment of resistant arterial hypertension
Václavík, J., Kociánová, E., & Táborský, M. (2011) · Cor et Vasa · doi:10.33678/cor.2011.085 · Cited by 4
Turkish Society of Cardiology Consensus Paper on Evaluation and Treatment of Resistant Hypertension
Şahinarslan, A. (2020) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2020.74154 · Cited by 4
Spironolactone and resistant hypertension
Williams, J. S. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.26 · Cited by 4
Ruilope, L. M., & Segura, J. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.522992 · Cited by 4
Detection and Treatment of Resistant Hypertension
Segura, J., de la Sierra, A., & Ruilope, L. M. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0136-0 · Cited by 4
Carter, B. L., & Ernst, M. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00022-6 · Cited by 4
Hipertensión arterial resistente
Armario, P., Oliveras, A., & de la Sierra, A. (2013) · Revista Clínica Española · doi:10.1016/j.rce.2013.05.001 · Cited by 3
Hage, F. G., Mansur, S. J., & Oparil, S. (2011) · Therapy · doi:10.2217/thy.11.20 · Cited by 3
Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?
Prosser, H. C. G., Gregory, C., Hering, D., Hillis, G. S., Perry, G. J., Rosman, J. B., Schultz, C. J., Thomas, M., Watts, G. F., & Schlaich, M. P. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0728-z · Cited by 3
do Carmo, J. M., da Silva, A. A., & Hall, J. E. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa170 · Cited by 3
Evidence-based approach for managing hypertension in type 2 diabetes
Gabbay, R. (2010) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s6984 · Cited by 3
Hipertensión arterial resistente
Armario, P., Oliveras, A., & de la Sierra, A. (2014) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2013.12.002 · Cited by 3
Yagi, S., Akaike, M., Aihara, K., Fukuda, D., Ishida, M., Ise, T., Niki, T., Sumitomo-Ueda, Y., Yamaguchi, K., Iwase, T., et al. (2013) · Europe PMC (PubMed Central) · Cited by 3
Resistant Hypertension: A Comprehensive Overview
Jentzer, J. C. (2013) · Journal of Hypertension Open Access · doi:10.4172/2167-1095.1000111 · Cited by 3
Medical Management of Renovascular Disease
Canzanello, V. J. (2014) · Springer eBooks · doi:10.1007/978-1-4471-2810-6_19 · Cited by 3
ALDOSTERONE AND OBESITY: WHERE TO LOOK FOR THE KEY TO THERAPY?
Vatutin, N. T., Shevelok, A. N., & Degtiarova, G. E. (2016) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2016-6-4-21-29 · Cited by 3
Mineralocorticoid Receptor in Calcium Handling of Vascular Smooth Muscle Cells
Salazar-Enciso, R., Camacho‐Concha, N., Mesquita, T., Falcón, D., Bénitah, J., Gomez, A. M., & Rueda, A. (2018) · InTech eBooks · doi:10.5772/intechopen.79556 · Cited by 3
Armario, P., Oliveras, A., & de la Sierra, A. (2013) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2013.07.005 · Cited by 3
Waeber, B., & Feihl, F. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.01800 · Cited by 3
Prevalence of Apparent Treatment-Resistant Hypertension
Jones, D. W., Clark, D., & Wofford, M. R. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12271 · Cited by 3
Püşüroğlu, H. (2023) · Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · doi:10.5543/tkda.2023.60464 · Cited by 2
Tsioufis, K. P., Kyriakoulis, K. G., Vakka, A., Stamataki, N., Tatakis, F., Konstantinidis, D., Mihas, C. C., Soulaidopoulos, S. S., Kasiakogias, A., Kordalis, A., et al. (2026) · Hypertension · doi:10.1161/hypertensionaha.126.26756 · Cited by 2
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7380-0_5 · Cited by 2
American Society of Hypertension Scientific Statements Addressing Resistant Hypertension
Turner, J. R., & Lee, J. (2015) · Journal of Clinical Hypertension · doi:10.1111/jch.12617 · Cited by 3
Belly fat and resistant hypertension
Jordan, J., & Grassi, G. M. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e328339b8d9 · Cited by 2
Current diagnosis and treatment of primary aldosteronism
Kaplan, N. M. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.135 · Cited by 2
Treatment of Resistant Hypertension. Which Additional Antihypertensive Drugs?
Burnier, M., Bertschi, A. P., & Wuerzner, G. (2013) · Springer eBooks · doi:10.1007/978-88-470-5415-8_10 · Cited by 2
The Long-Term Effects of RAAS Blockade on Renal Function
Cerezo, C., & Ruilope, L. M. (2012) · Springer eBooks · doi:10.1007/978-88-470-2601-8_35 · Cited by 2
Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: A Meta- Analysis
Macedo, F. (2013) · International Journal of Cardiovascular Research · doi:10.4172/2324-8602.1000116 · Cited by 2
Mineralocorticoid receptor antagonism as an add-on treatment for resistant hypertension
Rossi, G. P., & Maiolino, G. (2014) · Hypertension Research · doi:10.1038/hr.2014.139 · Cited by 2
Prado, J. C., Ruilope, L. M., & Segura, J. (2016) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2016.05.003 · Cited by 2
Lee, J. Y., Kim, D. Y., Lee, E. K., Lee, S.-Y., Lee, H. J., Jeong, J. H., & Kim, J. Y. (2018) · Journal of the Korean Ophthalmological Society · doi:10.3341/jkos.2018.59.6.511 · Cited by 2
Hipertensão resistente: abordagem clínica
Muxfeldt, E. S., Chedier, B., & Rodrigues, C. I. S. (2018) · Revista da Faculdade de Ciências Médicas de Sorocaba · doi:10.23925/1984-4840.2018v20i3a3 · Cited by 2
Self-citationSantos, L. E. G., Elliott, W. J., Setaro, J. F., & Black, H. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2766-1.00044-2 · Cited by 2
What is new in the management of resistant hypertension?
Pimenta, E., & Stowasser, M. (2011) · Therapy · doi:10.2217/thy.11.14 · Cited by 2
Alterations in glucocorticoid homeostasis following sleeve gastrectomy in male mice
Moser, S. O., Moscalu, A., Roberts, C. F., Späne, P. M., Winter, D. V., Joos, F. L., Gómez, C., Sheu, E. G., & Odermatt, A. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00385.2025 · Cited by 1
Evaluation of the ASPIRANT trial
Grassi, G. M. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.740457 · Cited by 1
Sica, D. A. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0224-z · Cited by 1
Management of Resistant Hypertension
Elliott, W. J. (2011) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-011-0194-0 · Cited by 1
Body mass index as a determinant for metabolic-related changes in resistant hypertension
Pansani, I. F., de Faria, A. P., Modolo, R., & Moreno, H. (2015) · Cited by 1
Patient with Resistant Hypertension
Segura, J. (2019) · Practical case studies in hypertension management · doi:10.1007/978-3-030-02741-4_6 · Cited by 1
Management of resistant hypertension
Holaj, R. (2011) · Cor et Vasa · doi:10.33678/cor.2011.108 · Cited by 1
Arioglu‐Inan, E., & Kayki‐Mutlu, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00162-6 · Cited by 1
Ahmed, M. I., Guichard, J. L., & Calhoun, D. A. (2011) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-011-0177-1 · Cited by 1
Эдуардовна, Д. И., Rodionov, A. V., & Fomin, V. V. (2022) · Consilium Medicum · doi:10.26442/20751753.2022.10.201856 · Cited by 1
Treatment of Resistant Hypertension
Seravalle, G., Grassi, G. M., & Mancia, G. (2018) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-59918-2_37 · Cited by 1
Obesity-Hypertension Physiopathology and Treatment: A Forty-Year Retrospect
Owen, J., Morse, S., McLean, A., & Reisin, E. (2018) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-75310-2_15 · Cited by 1
Metadata
- Authors
- de Souza, F., Muxfeldt, E., Fiszman, R., & Salles, G.
- Affiliations
- From the Hypertension Program, University Hospital Clementino Fraga Filho, Medical School, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
- Universidade Federal do Rio de Janeiro (BR)
- Venue
- Hypertension
- Published
- 2010-01
- Volume
- 55
- Issue
- 1
- Pages
- 147-152
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2135100154
- Cited by
- 234
- References
- 32
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 6 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 10 · 2019: 8 · 2018: 11 · 2017: 13 · 2016: 18 · 2015: 19 · 2014: 26 · 2013: 31 · 2012: 26
- FWCI
- 15.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Hypertension (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- spironolactone, resistant hypertension, antihypertensive therapy, ambulatory blood pressure monitoring, blood pressure reduction, predictors of treatment response, waist circumference, abdominal obesity, arterial stiffness, pulse wave velocity, serum potassium, aldosterone, adverse effects
- MeSH terms
- Blood Pressure, Breast Diseases, Diuretics, Follow-Up Studies, Gynecomastia, Humans, Hypertension, Prospective Studies, Spironolactone, Multivariate Analysis, Linear Models, Treatment Outcome, Blood Pressure Monitoring, Ambulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
